| 1.69 -0.03 (-1.74%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.45 | 1-year : | 2.86 |
| Resists | First : | 2.09 | Second : | 2.45 |
| Pivot price | 1.69  |
|||
| Supports | First : | 1.56 |
Second : | 1.24 |
| MAs | MA(5) : | 1.76 |
MA(20) : | 1.64 |
| MA(100) : | 1.41 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 70.3 |
D(3) : | 73.9 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 3.13 | Low : | 0.59 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MBAI ] has closed above bottom band by 48.1%. Bollinger Bands are 48.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.76 - 1.77 | 1.77 - 1.78 |
| Low: | 1.61 - 1.62 | 1.62 - 1.63 |
| Close: | 1.67 - 1.69 | 1.69 - 1.71 |
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. The company was incorporated in 2004 and is based in Isfiya, Israel.
Tue, 02 Dec 2025
Check-Cap ticker changes to MBAI as company shifts to embodied AI focus - Investing.com Australia
Mon, 17 Nov 2025
Check-Cap shareholders approve merger with MBody AI and company name change - Investing.com
Thu, 06 Nov 2025
RETRANSMISSION: Check-Cap and MBody AI Advance Toward Closing Transformational Merger - TMX Newsfile
Thu, 16 Oct 2025
Check-Cap regains Nasdaq compliance and postpones annual meeting following merger announcement - Investing.com
Fri, 14 Aug 2020
CHEK - Check Cap Latest Stock News & Market Updates - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 6 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 20.8 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 166 (K) |
| Shares Short P.Month | 208 (K) |
| EPS | -4.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.6 % |
| Return on Equity (ttm) | -226.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.4 |
| PEG Ratio | 0 |
| Price to Book value | -6.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|